Galderma’sNemluvio(nemolizumab)DemonstratesLong-TermDiseaseControlinPrurigoNodularisuptoThreeYears
===2026/2/27 17:48:31===
a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.10-12It is estimated to affect between 7-111 people per 100,000 in the EU depending on the country and up to 181,000 people in the U.S.13-16The majority of patients report that the persistent itch negatively impacts their quality of life.17Furthermore, the intense itch associated with prurigo nodularis results in significant sleep disturbance and further contributes to reduced quality of life.18,19
About Galerma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and p
=*=*=*=*=*=
当前为第7/12页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页